489 related articles for article (PubMed ID: 34414120)
1. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.
Zhu XD; Huang C; Shen YH; Ji Y; Ge NL; Qu XD; Chen L; Shi WK; Li ML; Zhu JJ; Tan CJ; Tang ZY; Zhou J; Fan J; Sun HC
Liver Cancer; 2021 Jul; 10(4):320-329. PubMed ID: 34414120
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
3. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Zhu XD; Huang C; Shen YH; Xu B; Ge NL; Ji Y; Qu XD; Chen L; Chen Y; Li ML; Zhu JJ; Tang ZY; Zhou J; Fan J; Sun HC
Ann Surg Oncol; 2023 May; 30(5):2782-2790. PubMed ID: 36178565
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.
Yi Y; Sun BY; Weng JL; Zhou C; Zhou CH; Cai MH; Zhang JY; Gao H; Sun J; Zhou J; Fan J; Ren N; Qiu SJ
Front Oncol; 2022; 12():1046584. PubMed ID: 36505772
[TBL] [Abstract][Full Text] [Related]
5. Downstaging and laparoscopic hepatectomy plus intraoperative radiofrequency ablation for the treatment of initially unresectable multifocal hepatocellular carcinomas.
Wang J; Luo H; Yi L; Yang P; Zeng X
Front Surg; 2023; 10():1340657. PubMed ID: 38283063
[TBL] [Abstract][Full Text] [Related]
6. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy.
Yang X; Xu H; Zuo B; Yang X; Bian J; Long J; Wang D; Zhang J; Ning C; Wang Y; Xun Z; Wang Y; Lu X; Mao Y; Sang X; Zhao H
Hepatobiliary Surg Nutr; 2021 Aug; 10(4):434-442. PubMed ID: 34430522
[TBL] [Abstract][Full Text] [Related]
7. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients.
Lin KY; Lin ZW; Chen QJ; Luo LP; Zhang JX; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Zhang JY; You WY; Wang B; You PH; Lin KC; Yang T; Zeng YY
Hepatol Int; 2023 Dec; 17(6):1477-1489. PubMed ID: 37382760
[TBL] [Abstract][Full Text] [Related]
8. Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1709-1721. PubMed ID: 37817914
[TBL] [Abstract][Full Text] [Related]
9. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
[TBL] [Abstract][Full Text] [Related]
11. Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy.
Zhao CK; Guan X; Pu YY; Zhou BY; Wang LF; Sun YK; Yin HH; Xia HS; Wang X; Han H; Xu HX
Ultrasound Med Biol; 2024 Jan; 50(1):142-149. PubMed ID: 37852872
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
13. Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study.
Zhang J; Zhang X; Mu H; Yu G; Xing W; Wang L; Zhang T
Front Oncol; 2021; 11():729764. PubMed ID: 34868921
[TBL] [Abstract][Full Text] [Related]
14. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients.
Zhang W; Hu B; Han J; Wang Z; Ma G; Ye H; Yuan J; Cao J; Zhang Z; Shi J; Chen M; Wang X; Xu Y; Cheng Y; Tian L; Wang H; Lu S
Front Oncol; 2021; 11():747950. PubMed ID: 34737958
[TBL] [Abstract][Full Text] [Related]
15. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
16. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
[TBL] [Abstract][Full Text] [Related]
17. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis.
Huang C; Zhu XD; Shen YH; Wu D; Ji Y; Ge NL; Chen LL; Tan CJ; Zhou J; Fan J; Sun HC
Biomark Res; 2021 Mar; 9(1):19. PubMed ID: 33743822
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients.
Zou J; Huang P; Ge N; Xu X; Wang Y; Zhang L; Chen Y
J Gastrointest Oncol; 2022 Aug; 13(4):1898-1906. PubMed ID: 36092355
[TBL] [Abstract][Full Text] [Related]
19. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma.
Lau WY; Leung TW; Lai BS; Liew CT; Ho SK; Yu SC; Tang AM
Ann Surg; 2001 Feb; 233(2):236-41. PubMed ID: 11176130
[TBL] [Abstract][Full Text] [Related]
20. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability.
Lau WY; Lai EC
Ann Surg Oncol; 2007 Dec; 14(12):3301-9. PubMed ID: 17891443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]